

DAD1 C, Sig=225,4 Ref=off
mAU
x10^3
Time [min]
4.363
4.215
4.544
4.961
5.471
6.106
6.694
3.691

Figure 1A



CS_216_13
From the sample holder
Amorphous halo
Position [°2Theta]
0
100
200
10
20
30
40
50

Figure 1B




Figure 2A




Figure 2B




Figure 3



CS-194-13
DMSO-d6
EtOAc
EtOAc
EtOAc
7.35
1.64
1.64
2.85
8.23
6.83
19.52
3.56
2.62
3.25
1.00
0.89
2.05
0.93
2.28
3.10
f1 (ppm)

Figure 3A




Figure 4




Figure 4A



PPM
2
4
6
8
10
21.47
17.47
1.001.10
6.41
17.17
12.48
4.73
11.15
9.84
1.00
0.97
1.05
1.04
1.382
1.425
1.468
2.299
2.805
3.349
3.453
4.248
4.265
4.793
4.811
4.829
5.014
6.847
6.854
6.877
6.882
6.947
6.953
6.969
6.975
7.119
7.121
7.141
7.143
7.232
7.234
7.252
7.275
7.425
7.430
7.444
7.446
7.460
7.465
7.502
7.523
7.544

Figure 4B



0.000
1.426
1.354
2.838
3.035
4.973
6.844
6.850
6.872
6.878
7.117
7.136
7.139
7.254
7.272
7.277
7.426
7.447
7.466
7.514
15.81
1.01
3.00
21.91
14.32
2.92
1.98
3.04
1.59
3.83
1.47
PPM
2
4
6
8
10
12
14

Figure 4C




Figure 5



LNB 1213-72-26
DMSO-d6
TBME
TBME
5.83
5.52
1.55
1.63
4.56
1.95
1.52
1.04
2.07
2.57
2.27
5.88
1.54
1.60
2.26
3.12
3.19
1.00
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
f1 (ppm)

Figure 5A



CS_062_14
From the sample holder
Amorphous halo
200
100
0
10
20
30
40
50
Position [°2Theta]

Figure 6



Pretreatment

Figure 7
Nose fully cleared after 28 days of treatment



28 days after treatment
Figure 7A

Figure 8
Full healing after 28 days treatment: feet pads normal (normal gait resumed within a few days)



Pretreatment



28 days after treatment
Figure 8A